Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. - Wikidata - thesis-toulmin - TriplyDB

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

http://www.wikidata.org/entity/Q34088600

about

Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception The Alzheimer's disease neuroimaging initiative: progress report and future plans Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging.A Novel Study Paradigm for Long-term Prevention Trials in Alzheimer Disease: The Placebo Group Simulation Approach (PGSA): Application to MCI data from the NACC database.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2 Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.Quantitative structural MRI for early detection of Alzheimer's disease.The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.Enrichment and stratification for predementia Alzheimer disease clinical trials.The relationship between regional brain volumes and the extent of coronary artery disease in mild cognitive impairment Nonlinear registration of longitudinal images and measurement of change in regions of interest Improved statistical power of Alzheimer clinical trials by item-response theory: proof of concept by application to the activities of daily living scale.Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease.Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.Multilocus genetic profiling to empower drug trials and predict brain atrophy.Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI.White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy.Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.Power calculations for clinical trials in Alzheimer's disease.Power analysis to detect treatment effects in longitudinal clinical trials for Alzheimer's disease.Proof of concept demonstration of optimal composite MRI endpoints for clinical trials.The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design.Patterns of progressive atrophy vary with age in Alzheimer's disease patients.

P2860

Q24594531-8A54BE4C-2C66-4E55-B2E3-D574E1F9EDDD Q27006831-D5119C09-654F-42EC-8F79-9842C0719E31 Q28749585-A6900F33-EFE5-4030-9915-B1789D27D721 Q30354417-84C81C93-AA69-4E1C-AF53-2190BBB42C0C Q30881418-87258F3D-A0A3-4DF5-9BDE-D62E53991DB1 Q30971403-1BB0B394-4D84-44F5-87D9-698312BE11DC Q30981669-990D43E2-B09F-4B74-AF44-FD675CC8C566 Q33572446-5B0E2628-2758-4AF0-860C-6E14696AEDFD Q33729033-10F4B5B6-4822-4F5D-AFA0-91CA717229F8 Q34065449-1AB3AE2C-50BD-4905-B6C0-58CFC3232A1F Q34364368-D7D9B0C4-4B1D-403C-A5F6-FCC15E8EFC9D Q34452239-9383508D-0FCB-42AC-885C-C32A18FDA828 Q34529816-ADD719D7-70EA-4C0F-819E-C2564302B6B0 Q35046222-683D9688-1DEA-4753-BCF4-A58103AB5A8B Q35185169-CC735F62-500E-4330-8BB4-79489B9D1147 Q36093127-60CA4C9E-044C-46C9-8A3B-5EBD53232670 Q36143793-3EE6406D-9060-446C-B32A-E17FFEE0860A Q37184374-E2BF455F-867A-47BD-AA7B-FB6B696A6CBF Q37195596-F47646E1-855C-4A78-99FC-72879F7074A4 Q37664085-1942F173-A681-4697-9291-F01C3690AF15 Q37693470-797DCEEF-5737-4DC2-B625-58ECA88CF07E Q37942446-782DE59F-B119-4371-BD4A-9CFF4933CCF0 Q41502500-574EA7A5-606F-4026-BBCB-8B6CE1768401 Q42314567-80C6CD7B-17AF-4D5B-95C9-0A34649B22F7 Q47134402-8212739C-DEC1-4D51-9FBB-348C5F3E10F1 Q47342494-0C795B47-611E-40B8-8F3A-6AD452606394

P2860

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

http://www.wikidata.org/entity/Q34088600

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

@ast

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

@en

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

@nl

type

label

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

@ast

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

@en

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

@nl

prefLabel

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

@ast

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

@en

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

@nl

P1433

Q34088600-3E588257-58E0-41F6-9054-8A3996ACDB75

P1476

Q34088600-3E3CF03F-B491-4CB5-BB3D-43AD4EC43CD7

P2093

Q34088600-078E1BD3-8AA7-4AE3-8553-E902ECCC1FA4

Q34088600-495E5D99-5439-4E04-99B9-9E6515B4D2EC

Q34088600-5EF3030A-6C89-4380-9FD9-D3019FBC190B

Q34088600-6D9E8DCA-50FB-40BE-B38F-F5C3395576A0

Q34088600-9C47FC42-C901-412A-BE4B-C4C91E45FAFE

Q34088600-C4352648-D33B-4DE6-A853-511FEE1254A4

Q34088600-E0D0ADA0-F27A-47F6-9487-9953005FA1E8

Q34088600-F3E45B75-0332-4044-9D0E-A276331AFF94

P2860

Q34088600-0002F484-1C9E-46AB-A11B-890F851FF184

Q34088600-01823B98-733D-4AB9-BE32-7E70C3537FD5

Q34088600-03ACF4F2-A408-43DA-AAD3-96CE702B2A6D

Q34088600-06813E1D-964A-4DCA-9DB2-B636975836F7

Q34088600-071A974C-C363-4339-97AB-6E013693AC3C

Q34088600-07A8AAC3-AF76-4F19-84C6-94DA2B1F6E8E

Q34088600-09727FC7-4906-4FDD-8CB7-29CF27B98338

Q34088600-1D25E56D-D5D1-49F0-A914-777B034AE1CB

Q34088600-239FAF9A-B4FE-4BFF-B259-8581DCE708EA

Q34088600-29729C8D-0343-4AF4-99EB-BA14E910EC74

P304

Q34088600-0534C82D-285D-4003-885B-FB4DDC32B997

P31

Q34088600-4B5E81DA-4DBE-4CFD-BDC9-2ADDF3347FE3

P356

Q34088600-D811C905-50E0-4990-AD87-6F8BE1F67585

P407

Q34088600-6ADBA966-D3A6-4055-8E2D-567934B7415A

P433

Q34088600-1A833BFF-4557-48DC-AE1E-654F2C8A7758

P478

Q34088600-29CE39F3-BBF1-408D-BB20-4888B9FA1757

P50

Q34088600-107EF943-6B16-4140-AC19-DBF5FC22B26D

Q34088600-50A22359-399A-429A-8C34-935A688D2FE1

Q34088600-95BE91E6-FB26-4682-BF02-7484DB43A8DC

Q34088600-EB8D39A1-1078-4D53-8613-268D1ADC321A

P577

Q34088600-53421238-0F48-419B-86D6-8F2272FBEE28

P5875

Q34088600-44D56E73-F8A2-4635-9912-489B1434A4B3

P698

Q34088600-FD21E0F1-3C01-4E55-AF1C-4A48ED683018

P921

Q34088600-6DF495B5-5C60-416B-9C63-142D2D2FADC5

Q34088600-C4D1FAF4-0250-4489-9E85-0AEF5D4B5A17

P932

Q34088600-A23FA89E-A222-4FF9-A131-83883EB8C433

P356

WAD.0B013E3181D1B814

P1433

Alzheimer Disease and Associated Disorders

P1476

Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.

@en

P2093

Alain K Koyama

http://www.w3.org/2001/XMLSchema#string

Alzheimerʼs Disease Neuroimaging Initiative

http://www.w3.org/2001/XMLSchema#string

David P Salmon

http://www.w3.org/2001/XMLSchema#string

Donald J Hagler

http://www.w3.org/2001/XMLSchema#string

J Cooper Roddey

http://www.w3.org/2001/XMLSchema#string

James B Brewer

http://www.w3.org/2001/XMLSchema#string

Linda K McEvoy

http://www.w3.org/2001/XMLSchema#string

Steven D Edland

http://www.w3.org/2001/XMLSchema#string

P2860

Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline

MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment

The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Neuropathological stageing of Alzheimer-related changes

Cortical Surface-Based Analysis

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain

Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system

An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest

P304

269-277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/WAD.0B013E3181D1B814

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Christine Fennema-Notestine

Dominic Holland

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45494521

http://www.w3.org/2001/XMLSchema#string

P698

20683184

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2929320

http://www.w3.org/2001/XMLSchema#string